First Manhattan Co. reduced its holdings in shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) by 7.5% during the first quarter, HoldingsChannel reports. The firm owned 472,300 shares of the specialty pharmaceutical company’s stock after selling 38,200 shares during the period. First Manhattan Co.’s holdings in Foamix Pharmaceuticals were worth $1,771,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also made changes to their positions in the company. Perceptive Advisors LLC lifted its holdings in shares of Foamix Pharmaceuticals by 50.0% during the fourth quarter. Perceptive Advisors LLC now owns 4,661,824 shares of the specialty pharmaceutical company’s stock valued at $15,850,000 after purchasing an additional 1,554,400 shares in the last quarter. Great Point Partners LLC lifted its holdings in shares of Foamix Pharmaceuticals by 0.4% during the fourth quarter. Great Point Partners LLC now owns 4,047,561 shares of the specialty pharmaceutical company’s stock valued at $14,531,000 after purchasing an additional 17,293 shares in the last quarter. Stonepine Capital Management LLC lifted its holdings in shares of Foamix Pharmaceuticals by 134.7% during the fourth quarter. Stonepine Capital Management LLC now owns 1,293,177 shares of the specialty pharmaceutical company’s stock valued at $4,643,000 after purchasing an additional 742,099 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Foamix Pharmaceuticals during the third quarter valued at $6,616,000. Finally, Sofinnova Investments Inc. lifted its holdings in shares of Foamix Pharmaceuticals by 24.5% during the fourth quarter. Sofinnova Investments Inc. now owns 832,293 shares of the specialty pharmaceutical company’s stock valued at $2,987,000 after purchasing an additional 163,674 shares in the last quarter. 59.76% of the stock is currently owned by hedge funds and other institutional investors.
In other Foamix Pharmaceuticals news, insider Matthew T. Wiley purchased 13,440 shares of the stock in a transaction dated Tuesday, March 5th. The shares were purchased at an average cost of $3.76 per share, with a total value of $50,534.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have sold 9,311 shares of company stock worth $34,916. Corporate insiders own 2.95% of the company’s stock.
Shares of NASDAQ:FOMX opened at $3.44 on Wednesday. The firm has a market cap of $200.07 million, a PE ratio of -2.02 and a beta of 1.70. Foamix Pharmaceuticals Ltd has a 1 year low of $3.21 and a 1 year high of $7.60.
A number of research analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $15.00 price target on shares of Foamix Pharmaceuticals in a report on Tuesday, April 2nd. Cowen set a $30.00 price target on Foamix Pharmaceuticals and gave the company a “buy” rating in a report on Friday, March 1st. Finally, HC Wainwright set a $12.00 price target on Foamix Pharmaceuticals and gave the company a “buy” rating in a report on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $14.75.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2019/04/17/first-manhattan-co-has-1-77-million-holdings-in-foamix-pharmaceuticals-ltd-fomx.html.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Recommended Story: How to find the components of the quick ratio
Want to see what other hedge funds are holding FOMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX).
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.